Imbalance of anti-inflammatory (resolving D1) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017
Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014
Evaluation of lipoxin A4 and nitric oxide as inflammatory mediators in bronchial asthma Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015
Assessment of sputum prostaglandins and leukotrienes in COPD exacerbations Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013
Correlation of fractional exhaled nitric oxide (FeNO) and peripheral blood eosinophils (PBE) in refractory asthma Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014
Measurements of prostaglandins E2 and D2 and their metabolites in exhaled breath condensate following bronchial provocation with aspirin in asthmatics Source: Annual Congress 2013 –Genetics and mechanisms of, and tests for, allergy Year: 2013
Relationships between exhaled nitric oxide and atopic profiles (mono-sensitization/poly-sensitization) in asthmatic patients Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Increased exhaled cysteinyl-leukotrienes, leukotriene B4 and 8-isoprostane in exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Validation of assays for inflammatory mediators in exhaled breath condensate Source: Eur Respir J 2008; 31: 943-948 Year: 2008
Additive contribution of exhaled nitric oxide and sputum eosinophils to airway responsiveness Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Concomitant use of fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) as markers for predicting asthma exacerbation Source: International Congress 2014 – Asthma: clinical problems Year: 2014
Cysteinyl leukotrienes and leukotriene B4 in expired breath condensate in patients with chronic asthma treated with montelukast Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Saliva is one likely source of leukotriene B4 in exhaled breath condensate Source: Eur Respir J 2006; 28: 1229-1235 Year: 2006
Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Measurement of tumor necrosis factor (TNF)α, leukotriene B4 (LTB4), and interleukin 8 (IL8) in the exhaled breath condensate (EBC) in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 584s Year: 2007
Combination of elevated exhaled nitric oxide and serum eosinophil cationic protein identifies asthma patients at risk for exacerbation Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015
Comparison of eicosanoids in sputum, bronchoalveolar lavage and exhaled breath condensate Source: International Congress 2014 – Airway biomarkers Year: 2014
Further evidence that FeNO directed therapy reduces asthma exacerbations Source: International Congress 2014 – Airway biomarkers Year: 2014
Hydrogen sulfide (H2 S) in sputum and serum as a novel biomarker of COPD Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014
Exhaled breath temperature(EBT) in asthmatic patients: Influence of severity and underlying mechanisms Source: International Congress 2016 – Airway biomarkers Year: 2016